

25th October, 2024

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2024

The Presentation on unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2024 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI
COMPANY SECRETARY

Encl : A/a

TORRENT PHARMACEUTICALS LIMITED

CIN: L24230GJ1972PLC002126

Reg.Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,
www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com



Q2 FY 2024-25

Revenues: Summary



Revenue: Summary

Revenues (Rs cr)	Q2 FY25	Q2 FY24	Gr%
India	1,632	1,444	13%
United States	268	248	8%
Germany	288	266	8%
Brazil	263	252	4%
Others	438	450	-3%
Total	2,889	2,660	9%



Revenue: Summary

Revenues (Rs cr)	H1 FY25	H1 FY24	Gr%
India	3,267	2,870	14%
United States	527	541	-3%
Germany	572	525	9%
Brazil	459	442	4%
Others	923	873	6%
Total	5,748	5,251	9%

